Acute Coronary Syndrome - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Acute Coronary Syndrome - Pipeline Review, H2 2015’, provides an overview of the Acute Coronary Syndrome’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Coronary Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Coronary Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Acute Coronary Syndrome Overview
- Therapeutics Development
- Pipeline Products for Acute Coronary Syndrome - Overview
- Pipeline Products for Acute Coronary Syndrome - Comparative Analysis
- Acute Coronary Syndrome - Therapeutics under Development by Companies
- Acute Coronary Syndrome - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Acute Coronary Syndrome - Products under Development by Companies
- Acute Coronary Syndrome - Companies Involved in Therapeutics Development
- advanceCor GmbH
- Arena Pharmaceuticals, Inc.
- Artery Therapeutics, Inc.
- Athera Biotechnologies AB
- Bayer AG
- Cardiome Pharma Corp.
- Cerenis Therapeutics Holding SA
- Esperion Therapeutics, Inc.
- GlaxoSmithKline Plc
- Lee's Pharmaceutical Holdings Limited
- MedImmune, LLC
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
- The Medicines Company
- Vitae Pharmaceuticals, Inc.
- XOMA Corporation
- Acute Coronary Syndrome - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- 4-WF - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AEM-28 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AEM-28-02 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Artpep-2 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Biologics for Acute Coronary Syndrome - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CER-001 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- COR-2 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- COR-3 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- gevokizumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- losmapimod - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MDCO-216 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MEDI-6012 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PC-mAb - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PF-06282999 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PMC-6 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PR-15 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- rivaroxaban - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SD-970 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- temanogrel hydrochloride - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- tirofiban hydrochloride - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- VTP-38443 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ZK-001 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Acute Coronary Syndrome - Recent Pipeline Updates
- Acute Coronary Syndrome - Dormant Projects
- Acute Coronary Syndrome - Dormant Projects
- Acute Coronary Syndrome - Discontinued Products
- Acute Coronary Syndrome - Product Development Milestones
- Featured News & Press Releases
- May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding
- Apr 23, 2015: Medicure Announces Approval of Expanded Dosing Time For AGGRASTAT
- Oct 22, 2014: NICE draft guidance recommends rivaroxaban (Xarelto) to prevent blood clots in people who have had a heart attack
- Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals
- Aug 29, 2014: Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO in Addressing Critical Medical Needs
- Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome
- Jan 16, 2014: FDA Advisory Committee Recommends Against Approval of the Use of Oral Anticoagulant XARELTO to Reduce the Risk of Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndrome
- Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001
- Nov 14, 2013: Real-World Data Confirm Clinical Value of Bayer’s Novel Oral Anticoagulant Xarelto in Protecting Patients Against Blood Clots
- Oct 07, 2013: Regulatory Update on Bayer’s Xarelto (Rivaroxaban) 2.5 mg in ACS Indication
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Acute Coronary Syndrome, H2 2015
- Number of Products under Development for Acute Coronary Syndrome - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Comparative Analysis by Late Stage Development, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Development, H2 2015
- Products under Development by Companies, H2 2015
- Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H2 2015
- Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
- Acute Coronary Syndrome - Pipeline by Artery Therapeutics, Inc., H2 2015
- Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H2 2015
- Acute Coronary Syndrome - Pipeline by Bayer AG, H2 2015
- Acute Coronary Syndrome - Pipeline by Cardiome Pharma Corp., H2 2015
- Acute Coronary Syndrome - Pipeline by Cerenis Therapeutics Holding SA, H2 2015
- Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H2 2015
- Acute Coronary Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2015
- Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015
- Acute Coronary Syndrome - Pipeline by MedImmune, LLC, H2 2015
- Acute Coronary Syndrome - Pipeline by Pfizer Inc., H2 2015
- Acute Coronary Syndrome - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
- Acute Coronary Syndrome - Pipeline by The Medicines Company, H2 2015
- Acute Coronary Syndrome - Pipeline by Vitae Pharmaceuticals, Inc., H2 2015
- Acute Coronary Syndrome - Pipeline by XOMA Corporation, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Stage and Target, H2 2015
- Number of Products by Stage and Mechanism of Action, H2 2015
- Number of Products by Stage and Route of Administration, H2 2015
- Number of Products by Stage and Molecule Type, H2 2015
- Acute Coronary Syndrome Therapeutics - Recent Pipeline Updates, H2 2015
- Acute Coronary Syndrome - Dormant Projects, H2 2015
- Acute Coronary Syndrome - Dormant Projects (Contd..1), H2 2015
- Acute Coronary Syndrome - Discontinued Products, H2 2015
- Acute Coronary Syndrome - Discontinued Products (Contd..1), H2 2015
- List of Figures
- Number of Products under Development for Acute Coronary Syndrome, H2 2015
- Number of Products under Development for Acute Coronary Syndrome - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Top 10 Targets, H2 2015
- Number of Products by Stage and Top 10 Targets, H2 2015
- Number of Products by Top 10 Mechanism of Actions, H2 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
- Number of Products by Top 10 Routes of Administration, H2 2015
- Number of Products by Stage and Top 10 Routes of Administration, H2 2015
- Number of Products by Top 10 Molecule Types, H2 2015
- Number of Products by Stage and Top 10 Molecule Types, H2 2015
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBookOther tasks
